Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiation.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
08 Jan 2024
Historique:
received: 11 07 2023
revised: 31 12 2023
accepted: 02 01 2024
medline: 11 1 2024
pubmed: 11 1 2024
entrez: 10 1 2024
Statut: aheadofprint

Résumé

To quantify patient-reported 2-year intestinal toxicity (IT) from pelvic nodal irradiation (PNI) for prostate cancer. The association between baseline/acute symptoms and 2-year worsening was investigated. Patient-reported IT was prospectively assessed through the Inflammatory Bowel Disease Questionnaire (IBDQ), filled in at baseline, radiotherapy mid-point and end, at 3 and 6 months and every 6 months until 5 years. Two-year deterioration of IBDQ scores relative to the Bowel Domain was investigated for 400 patients with no severe baseline symptoms and with questionnaires available at baseline, 2 years, RT mid-point and/or end and at least three follow-ups between 3 and 18 months. The significance of the 2-year differences from baseline was tested. The association between baseline values and Δ In the IBDQ lower scores indicate worse symptoms. A significant (p<0.0001) 2-year mean worsening, mostly in the range of -0.2/-0.4 points on a 1-7 scale, emerged excepting one question (IBDQ29, "nausea/feeling sick"). This decline was independent of treatment intent while baseline values were associated with 2-year absolute scores. The Δ A modest but significant deterioration of two-year patient-reported intestinal symptoms from PNI compared to baseline was found. Patients experiencing more severe acute symptoms are at higher risk of symptom persistence at 2 years, with a much larger prevalence of clinically significant symptoms.

Sections du résumé

BACKGROUND AND PURPOSE OBJECTIVE
To quantify patient-reported 2-year intestinal toxicity (IT) from pelvic nodal irradiation (PNI) for prostate cancer. The association between baseline/acute symptoms and 2-year worsening was investigated.
MATERIALS AND METHODS METHODS
Patient-reported IT was prospectively assessed through the Inflammatory Bowel Disease Questionnaire (IBDQ), filled in at baseline, radiotherapy mid-point and end, at 3 and 6 months and every 6 months until 5 years. Two-year deterioration of IBDQ scores relative to the Bowel Domain was investigated for 400 patients with no severe baseline symptoms and with questionnaires available at baseline, 2 years, RT mid-point and/or end and at least three follow-ups between 3 and 18 months. The significance of the 2-year differences from baseline was tested. The association between baseline values and Δ
RESULTS RESULTS
In the IBDQ lower scores indicate worse symptoms. A significant (p<0.0001) 2-year mean worsening, mostly in the range of -0.2/-0.4 points on a 1-7 scale, emerged excepting one question (IBDQ29, "nausea/feeling sick"). This decline was independent of treatment intent while baseline values were associated with 2-year absolute scores. The Δ
CONCLUSION CONCLUSIONS
A modest but significant deterioration of two-year patient-reported intestinal symptoms from PNI compared to baseline was found. Patients experiencing more severe acute symptoms are at higher risk of symptom persistence at 2 years, with a much larger prevalence of clinically significant symptoms.

Identifiants

pubmed: 38199284
pii: S0167-8140(24)00009-4
doi: 10.1016/j.radonc.2024.110088
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110088

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Giuseppe Sanguineti (G)

Radiotherapy, IRCCS Istituto Nazionale dei Tumori "Regina Elena", Roma, Italy.

Maddalena Pavarini (M)

Medical Physics, IRCCS San Raffaele Scientific Institute, Milano, Italy.

Fernando Munoz (F)

Radiotherapy, Ospedale Regionale Parini-AUSL Valle d'Aosta, Aosta, Italy.

Alessandro Magli (A)

Radiotherapy, Azienda Ospedaliero Universitaria S. Maria della Misericordia, Udine, Italy.

Domenico Cante (D)

Radiotherapy, ASL TO4 Ospedale di Ivrea, Ivrea, Italy.

Elisabetta Garibaldi (E)

Radiotherapy, Ospedale Regionale Parini-AUSL Valle d'Aosta, Aosta, Italy.

Andrea Gebbia (A)

Medical Physics, IRCCS San Raffaele Scientific Institute, Milano, Italy.

Barbara Noris Chiorda (B)

Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Giuseppe Girelli (G)

Radiotherapy, Ospedale degli Infermi, Biella, Italy.

Elisa Villa (E)

Radiotherapy, Cliniche Gavazzeni-Humanitas, Bergamo, Italy.

Adriana Faiella (A)

Radiotherapy, IRCCS Istituto Nazionale dei Tumori "Regina Elena", Roma, Italy.

Justyna Magdalena Waskiewicz (J)

Radiotherapy, Comprensorio Sanitario di Bolzano, Bolzano, Italy.

Barbara Avuzzi (B)

Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Alice Pastorino (A)

Radiotherapy, A.O.SS. Antonio e Biagio, Alessandria, Italy.

Eugenia Moretti (E)

Medical Physics, Azienda sanitaria universitaria Friuli Centrale, Udine Italy.

Luciana Rago (L)

Radiotherapy, Centro di Riferimento Oncologico della Basilicata (IRCCS-CROB), Rionero in Vulture, Italy.

Teodora Statuto (T)

Laboratory of Clinical Research and Advanced Diagnostics, Centro di Riferimento Oncologico della Basilicata (IRCCS - CROB), Rionero in Vulture, Italy.

Marco Gatti (M)

Radiotherapy, Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia IRCCS, Candiolo, Italy.

Tiziana Rancati (T)

Unit of Data Science, Department of Epidemiology and Data Science, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Riccardo Valdagni (R)

Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Vittorio Luigi Vavassori (V)

Radiotherapy, Cliniche Gavazzeni-Humanitas, Bergamo, Italy.

Nadia Gisella Di Muzio (N)

Radiotherapy, IRCCS San Raffaele Scientific Institute, Milano, Italy; Medicine and Surgery, Vita-Salute San Raffaele University, Milano, Italy.

Claudio Fiorino (C)

Medical Physics, IRCCS San Raffaele Scientific Institute, Milano, Italy.

Cesare Cozzarini (C)

Radiotherapy, IRCCS San Raffaele Scientific Institute, Milano, Italy. Electronic address: cozzarini.cesare@hsr.it.

Classifications MeSH